Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BridgeBio’s Infigratinib Receives Breakthrough Therapy For Achondroplasia
Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 TKI in development for the treatment of achondroplasia in children.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2024
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BridgeBio Pharma Partners with Kyowa Kirin for $100M License On Infigratinib
Details : Under the terms of the agreements, Kyowa Kirin has an exclusive license to develop and commercialize BGJ398 (infigratinib) for achondroplasia, hypochondroplasia and other skeletal dysplasias in Japan.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : $100.0 million
July 02, 2024
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BridgeBio: Positive Phase 2 Results for Infigratinib in Achondroplasia
Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 TKI in development for the treatment of achondroplasia in children.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BGJ398 (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BGJ398 (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2023
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : QED Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.
Product Name : BGJ398
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : QED Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers and to target achondroplasia at its source.
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Helsinn To Present Data at Upcoming AMMF's 2022 European Cholangiocarcinoma Conference
Details : Truseltiq (Infigratinib) is a potent orally administered, selective, ATP‐competitive, kinase inhibitor of FGFRs, with highest affinity for FGFR 1, 2, and 3, is indicated for treatment of adults with previously treated metastatic cholangiocarcinoma with...
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2022
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Infigratinib (BGJ398), was well-tolerated with no serious adverse events (SAE) and no discontinuations due to adverse events (AE) including in Cohort 5 (dose: 0.25 mg/kg once daily) participants dosed to date, with a median duration of follow-up of 48.1 ...
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Truseltiq (infigratinib) was well-tolerated with no SAE and no discontinuations due to AE including in Cohort 5 participants dosed to date, with a median duration of follow-up of 48.1 weeks; only limited number of AEs were assessed as related to study dr...
Product Name : Truseltiq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable